Dermatology | Page 5 of 23 | Links Medicus Content Curation & Alerts in Medicine

Seminar: Monkeypox

In light of the 2022 global outbreak, @oriolmitja and colleagues provide an overview of epidemiology, clinical presentation, treatment, prevention, and more.

📌 https://t.co/gB0fcokA8D pic.twitter.com/Db3ZsU4ykt

— The Lancet (@TheLancet) November 22, 2022

Improving antimicrobial stewardship with penicillin allergy testing: a review of current practices and unmet needs.

27 Nov, 2022 | 22:25h | UTC

Improving antimicrobial stewardship with penicillin allergy testing: a review of current practices and unmet needs – JAC-Antimicrobial Resistance

Management of Patients with Suspected or Confirmed Antibiotic Allergy. Executive Summary of Guidance from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Allergy and Clinical Immunology (SEAIC), the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Intensive Medicine and Coronary Care Units (SEMICYUC) – Journal of Investigational Allergology and Clinical Immunology (PDF)

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

M-A: Most patients with allergy to Penicillin can be given Cefazolin

Systematic review: Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge

Penicillin allergy labels increase second-line broad-spectrum antibiotic prescribing for pediatric respiratory tract infections

Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy

Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule

Management of a surgical patient with a label of penicillin allergy: narrative review and consensus recommendations – British Journal of Anaesthesia

NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk

Cohort Study: Risk of Meticillin Resistant Staphylococcus Aureus and Clostridium Difficile in Patients with a Documented Penicillin Allergy

SR | Interventions for the long‐term prevention of hereditary angioedema attacks.

27 Nov, 2022 | 22:12h | UTC

Interventions for the long‐term prevention of hereditary angioedema attacks – Cochrane Library

Summary: Drug treatments for the prevention of attacks of hereditary angioedema – Cochrane Library

Commentary on Twitter

New #CochraneEvidence – Interventions for the long‐term prevention of #HereditaryAngioedema attacks #HAE @CochraneUK @CochraneLibrary @US_HAEA @UCSDHealth @HAEDAY @VSGBI @ChariteBerlin https://t.co/jYYjmG1eGH pic.twitter.com/2z522Bw5iZ

— Vascular Evidence (@Vasc_Evidence) November 7, 2022

Skin cancer in solid organ transplant recipients: a review for the non-dermatologist.

27 Nov, 2022 | 22:02h | UTC

Skin Cancer in Solid Organ Transplant Recipients: A Review for the Nondermatologist – Mayo Clinic Proceedings

Study shows there is substantial monkeypox transmission before symptoms appear.

25 Nov, 2022 | 12:43h | UTC

Transmission dynamics of monkeypox in the United Kingdom: contact tracing study – The BMJ

Editorial: The dynamics of monkeypox transmission – The BMJ

News Release: Evidence for “substantial” monkeypox transmission before symptoms – BMJ Newsroom

Commentaries:

Expert reaction to study looking at monkeypox transmission before symptoms appear – Science Media Centre

Study finds evidence of ‘considerable’ presymptomatic spread of monkeypox – The Guardian

RCT | Treatment of early Lyme Disease with doxycycline for 7 days is noninferior to treatment for 14 days.

23 Nov, 2022 | 14:06h | UTC

Treatment of erythema migrans with doxycycline for 7 days versus 14 days in Slovenia: a randomised open-label non-inferiority trial – The Lancet Infectious Diseases (link to abstract – $ for full-text)

Commentary: Shorter Duration of Antibiotics Noninferior for Lyme Disease – JAMA (free for a limited period)

Commentary on Twitter

New research: Treatment of erythema migrans with doxycycline for 7 days versus 14 days in Slovenia: a randomised open-label non-inferiority trialhttps://t.co/8lktc4gxzG pic.twitter.com/mP2e0Kn7C5

— The Lancet Infectious Diseases (@TheLancetInfDis) October 7, 2022

RCT | Efficacy and safety of Remibrutinib, a novel BTK inhibitor, for chronic spontaneous urticaria.

23 Nov, 2022 | 13:37h | UTC

Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria – The Journal of Allergy and Clinical Immunology

M-A | Global monkeypox case hospitalization rates.

21 Nov, 2022 | 14:36h | UTC

Global monkeypox case hospitalisation rates: A rapid systematic review and meta-analysis – eClinicalMedicine

Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series – The Lancet

Monkeypox — A Sobering Sentinel for Pandemic Preparedness and Sexual Health System Capacity – New England Journal of Medicine

CDC study shows healthcare workers have a low risk of infection after exposure to patients with monkeypox.

Monkeypox – New England Journal of Medicine

Diagnosis and Management of Monkeypox: A Review for the Emergency Clinician – Annals of Emergency Medicine

Monkeypox: disease epidemiology, host immunity and clinical interventions.

Monkeypox: A clinical update for paediatricians – Journal of Pediatrics and Child Health

Cohort Study | Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain.

CDC Report | Epidemiologic and clinical characteristics of Monkeypox cases in the US.

Update on the Monkeypox Outbreak – JAMA

Antivirals with Activity Against Monkeypox: A Clinically Oriented Review – Clinical Infectious Diseases

Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series – The BMJ

WHO Declares Global Public Health Emergency Over Monkeypox Virus Outbreak – Health Policy Watch

Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022 – New England Journal of Medicine

Monkeypox: A Contemporary Review for Healthcare Professionals – Open Forum Infectious Diseases

Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series.

21 Nov, 2022 | 14:35h | UTC

Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series – The Lancet

Commentaries:

First study of monkeypox infection in women provides new insights to inform public health response to ongoing outbreak – Queen Mary University of London

Study describes monkeypox in women; CDC warns of Tpoxx resistance – CIDRAP

Global monkeypox case hospitalisation rates: A rapid systematic review and meta-analysis – eClinicalMedicine

Monkeypox — A Sobering Sentinel for Pandemic Preparedness and Sexual Health System Capacity – New England Journal of Medicine

CDC study shows healthcare workers have a low risk of infection after exposure to patients with monkeypox.

Monkeypox – New England Journal of Medicine

Diagnosis and Management of Monkeypox: A Review for the Emergency Clinician – Annals of Emergency Medicine

Monkeypox: disease epidemiology, host immunity and clinical interventions.

Monkeypox: A clinical update for paediatricians – Journal of Pediatrics and Child Health

Cohort Study | Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain.

CDC Report | Epidemiologic and clinical characteristics of Monkeypox cases in the US.

Update on the Monkeypox Outbreak – JAMA

Antivirals with Activity Against Monkeypox: A Clinically Oriented Review – Clinical Infectious Diseases

Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series – The BMJ

WHO Declares Global Public Health Emergency Over Monkeypox Virus Outbreak – Health Policy Watch

Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022 – New England Journal of Medicine

Monkeypox: A Contemporary Review for Healthcare Professionals – Open Forum Infectious Diseases

CDC study shows healthcare workers have a low risk of infection after exposure to patients with monkeypox.

28 Oct, 2022 | 13:21h | UTC

Health Care Personnel Exposures to Subsequently Laboratory-Confirmed Monkeypox Patients — Colorado, 2022 – Morbidity and Mortality Weekly Report

Commentaries:

Clinicians at Low Risk of Acquiring Monkeypox From Patients – JAMA

Low risk of monkeypox spread noted in health workers – CIDRAP

Risk of Monkeypox Transmission Low in Health Care Settings – HealthDay

Review | Monkeypox.

27 Oct, 2022 | 12:36h | UTC

Monkeypox – New England Journal of Medicine

Diagnosis and Management of Monkeypox: A Review for the Emergency Clinician – Annals of Emergency Medicine

Monkeypox: disease epidemiology, host immunity and clinical interventions.

Monkeypox: A clinical update for paediatricians – Journal of Pediatrics and Child Health

Cohort Study | Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain.

CDC Report | Epidemiologic and clinical characteristics of Monkeypox cases in the US.

Update on the Monkeypox Outbreak – JAMA

Antivirals with Activity Against Monkeypox: A Clinically Oriented Review – Clinical Infectious Diseases

Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series – The BMJ

WHO Declares Global Public Health Emergency Over Monkeypox Virus Outbreak – Health Policy Watch

Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022 – New England Journal of Medicine

Monkeypox: A Contemporary Review for Healthcare Professionals – Open Forum Infectious Diseases

Commentary on Twitter

Monkeypox cases reported in the United Kingdom, Portugal, and Italy in May 2022 led the WHO to declare a global health emergency. The authors review the virology, epidemiology, clinical features, and treatment of monkeypox. https://t.co/dk2ZxxPsN7 pic.twitter.com/u3gzD6V7Bo

— NEJM (@NEJM) October 26, 2022

Two Phase 3, randomized, controlled trials of Ruxolitinib cream for vitiligo.

21 Oct, 2022 | 13:03h | UTC

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Ruxolitinib Cream Results in Greater Repigmentation in Vitiligo – HealthDay

Cohort Study | Use of straighteners and other hair products and incident uterine cancer.

20 Oct, 2022 | 12:28h | UTC

Use of Straighteners and Other Hair Products and Incident Uterine Cancer – JNCI: Journal of the National Cancer Institute

News Release: Hair straightening chemicals associated with higher uterine cancer risk – NIH News Releases

Commentaries:

Hair-straightening chemical products linked to increased uterine cancer risk in new study – CNN

Hair straightening chemicals may increase women’s risk of uterine cancer, study finds – NPR

Safety of Upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies.

19 Oct, 2022 | 14:14h | UTC

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies – Journal of Allergy and Clinical Immunology

M-A | Incidence of cutaneous adverse events with Phosphoinositide 3-Kinase inhibitors as adjuvant therapy in patients with cancer.

14 Oct, 2022 | 14:01h | UTC

Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysis – JAMA Oncology (free for a limited period)

M-A | Complications of hidradenitis suppurativa after surgical management.

13 Oct, 2022 | 13:40h | UTC

Complications of hidradenitis suppurativa after surgical management: A systematic review and meta-analysis – International Wound Journal

Commentary: Assessing Surgical Complications in Management of Hidradenitis Suppurativa – AJMC

RCT | Intravenous immune globulin reduces disease activity in dermatomyositis.

6 Oct, 2022 | 13:48h | UTC

Trial of Intravenous Immune Globulin in Dermatomyositis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

NEJM: trial of IVIG for autoimmune disorder dermatomyositis – MedicalResearch.com

IV Immune Globulin Bests Placebo for Dermatomyositis – Drugs.com

M-A | Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis.

6 Oct, 2022 | 13:37h | UTC

Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis – BMC Rheumatology

WAO/EAACI guideline for the management of hereditary angioedema.

4 Oct, 2022 | 14:34h | UTC

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update – Allergy

AAP Clinical Report | Controlling and treating head lice in children and adolescents.

3 Oct, 2022 | 14:04h | UTC

Head Lice – Pediatrics

News Release: American Academy of Pediatrics Updates Report on Controlling and Treating Head Lice in Children, Adolescents – American Academy of Pediatrics

Systematic Review | Laser therapy for treating hypertrophic and keloid scars – not enough evidence to guide recommendations.

30 Sep, 2022 | 12:27h | UTC

Laser therapy for treating hypertrophic and keloid scars – Cochrane Library

Summary: Laser therapy for hypertrophic and keloid scars – Cochrane Library

RCT | Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants.

28 Sep, 2022 | 13:35h | UTC

Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants—The STOP-AD randomised controlled trial – Allergy

Commentary: Early Use of Short-term Emollients Linked With Reduced Incidence of AD in High-risk Infants – AJMC

Commentary on Twitter

Can early barrier targeted interventions prevent development of #atopicdermatitis ?

Here’s our contribution.

After negative signals in BEEP and PreventADALL. We suggest earlier intervention with specific emollients may have a role.

More work neededhttps://t.co/GDscCeD1LS pic.twitter.com/ZqEqHMyhcW

— Alan Irvine (@irvinederm) August 27, 2022

Diagnosis and management of Monkeypox: a review for the emergency clinician.

26 Sep, 2022 | 12:07h | UTC

Diagnosis and Management of Monkeypox: A Review for the Emergency Clinician – Annals of Emergency Medicine

Monkeypox: disease epidemiology, host immunity and clinical interventions.

Monkeypox: A clinical update for paediatricians – Journal of Pediatrics and Child Health

Cohort Study | Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain.

CDC Report | Epidemiologic and clinical characteristics of Monkeypox cases in the US.

Update on the Monkeypox Outbreak – JAMA

Antivirals with Activity Against Monkeypox: A Clinically Oriented Review – Clinical Infectious Diseases

Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series – The BMJ

WHO Declares Global Public Health Emergency Over Monkeypox Virus Outbreak – Health Policy Watch

Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022 – New England Journal of Medicine

Monkeypox: A Contemporary Review for Healthcare Professionals – Open Forum Infectious Diseases

RCTs | Effect of Roflumilast cream vs. vehicle cream on chronic plaque psoriasis.

22 Sep, 2022 | 13:06h | UTC

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials – JAMA (free for a limited period)

Editorial: Roflumilast for Chronic Plaque Psoriasis – JAMA

Commentary: Study Suggests Roflumilast May Be Effective As Treatment For Plaque Psoriasis – HCPLive

Commentary on Twitter

Roflumilast cream resulted in better chronic plaque psoriasis clinical status compared with vehicle cream at 8 weeks; further research is needed to compare efficacy with other active treatments and to assess longer-term efficacy and safety. https://t.co/DyGNNjr5ea #Research pic.twitter.com/QnMcChnht6

— JAMA (@JAMA_current) September 21, 2022

RCT | Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis.

20 Sep, 2022 | 13:20h | UTC

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet

Commentary: Dupilumab Eases Atopic Dermatitis in Children Younger Than 6 Years – HealthDay

Stay Updated in Your Specialty